uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: Proof-of-concept in orthotopic xenograft model

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer : Proof-of-concept in orthotopic xenograft model. / Christensen, Anders; Juhl, Karina; Persson, Morten; Charabi, Birgitte Wittenborg; Mortensen, Jann; Kiss, Katalin; Lelkaitis, Giedrius; Rubek, Niclas; von Buchwald, Christian; Kjær, Andreas.

I: OncoTarget, Bind 8, Nr. 9, 12.2017, s. 15407-15419.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Christensen, A, Juhl, K, Persson, M, Charabi, BW, Mortensen, J, Kiss, K, Lelkaitis, G, Rubek, N, von Buchwald, C & Kjær, A 2017, 'uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: Proof-of-concept in orthotopic xenograft model', OncoTarget, bind 8, nr. 9, s. 15407-15419. https://doi.org/10.18632/oncotarget.14282

APA

Christensen, A., Juhl, K., Persson, M., Charabi, B. W., Mortensen, J., Kiss, K., ... Kjær, A. (2017). uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: Proof-of-concept in orthotopic xenograft model. OncoTarget, 8(9), 15407-15419. https://doi.org/10.18632/oncotarget.14282

Vancouver

Christensen A, Juhl K, Persson M, Charabi BW, Mortensen J, Kiss K o.a. uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: Proof-of-concept in orthotopic xenograft model. OncoTarget. 2017 dec;8(9):15407-15419. https://doi.org/10.18632/oncotarget.14282

Author

Christensen, Anders ; Juhl, Karina ; Persson, Morten ; Charabi, Birgitte Wittenborg ; Mortensen, Jann ; Kiss, Katalin ; Lelkaitis, Giedrius ; Rubek, Niclas ; von Buchwald, Christian ; Kjær, Andreas. / uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer : Proof-of-concept in orthotopic xenograft model. I: OncoTarget. 2017 ; Bind 8, Nr. 9. s. 15407-15419.

Bibtex

@article{b0e095db43e0443ca155d30ee1767b4d,
title = "uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: Proof-of-concept in orthotopic xenograft model",
abstract = "Purpose: Urokinase-like Plasminogen Activator Receptor (uPAR) is overexpressed in a variety of carcinoma types, and therefore represents an attractive imaging target. The aim of this study was to assess the feasibility of two uPAR-targeted probes for PET and fluorescence tumor imaging in a human xenograft tongue cancer model. Experimental design and results: Tumor growth of tongue cancer was monitored by bioluminescence imaging (BLI) and MRI. Either ICG-Glu-Glu-AE105 (fluorescent agent) or 64Cu-DOTA-AE105 (PET agent) was injected systemically, and fluorescence imaging or PET/CT imaging was performed. Tissue was collected for micro-fluorescence imaging and histology. A clear fluorescent signal was detected in the primary tumor with a mean in vivo tumor-to-background ratio of 2.5. Real-time fluorescence-guided tumor resection was possible, and sub-millimeter tumor deposits could be localized. Histological analysis showed co-localization of the fluorescent signal, uPAR expression and tumor deposits. In addition, the feasibility of uPARguided robotic cancer surgery was demonstrated. Also, uPAR-PET imaging showed a clear and localized signal in the tongue tumors. Conclusions: This study demonstrated the feasibility of combining two uPARtargeted probes in a preclinical head and neck cancer model. The PET modality provided preoperative non-invasive tumor imaging and the optical modality allowed for real-time fluorescence-guided tumor detection and resection. Clinical translation of this platform seems promising.",
keywords = "Head and neck cancer, Image-guided surgery, PET, Robotic surgery, Tumor margin assessment, uPAR",
author = "Anders Christensen and Karina Juhl and Morten Persson and Charabi, {Birgitte Wittenborg} and Jann Mortensen and Katalin Kiss and Giedrius Lelkaitis and Niclas Rubek and {von Buchwald}, Christian and Andreas Kj{\ae}r",
year = "2017",
month = "12",
doi = "10.18632/oncotarget.14282",
language = "English",
volume = "8",
pages = "15407--15419",
journal = "OncoTarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "9",

}

RIS

TY - JOUR

T1 - uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer

T2 - Proof-of-concept in orthotopic xenograft model

AU - Christensen, Anders

AU - Juhl, Karina

AU - Persson, Morten

AU - Charabi, Birgitte Wittenborg

AU - Mortensen, Jann

AU - Kiss, Katalin

AU - Lelkaitis, Giedrius

AU - Rubek, Niclas

AU - von Buchwald, Christian

AU - Kjær, Andreas

PY - 2017/12

Y1 - 2017/12

N2 - Purpose: Urokinase-like Plasminogen Activator Receptor (uPAR) is overexpressed in a variety of carcinoma types, and therefore represents an attractive imaging target. The aim of this study was to assess the feasibility of two uPAR-targeted probes for PET and fluorescence tumor imaging in a human xenograft tongue cancer model. Experimental design and results: Tumor growth of tongue cancer was monitored by bioluminescence imaging (BLI) and MRI. Either ICG-Glu-Glu-AE105 (fluorescent agent) or 64Cu-DOTA-AE105 (PET agent) was injected systemically, and fluorescence imaging or PET/CT imaging was performed. Tissue was collected for micro-fluorescence imaging and histology. A clear fluorescent signal was detected in the primary tumor with a mean in vivo tumor-to-background ratio of 2.5. Real-time fluorescence-guided tumor resection was possible, and sub-millimeter tumor deposits could be localized. Histological analysis showed co-localization of the fluorescent signal, uPAR expression and tumor deposits. In addition, the feasibility of uPARguided robotic cancer surgery was demonstrated. Also, uPAR-PET imaging showed a clear and localized signal in the tongue tumors. Conclusions: This study demonstrated the feasibility of combining two uPARtargeted probes in a preclinical head and neck cancer model. The PET modality provided preoperative non-invasive tumor imaging and the optical modality allowed for real-time fluorescence-guided tumor detection and resection. Clinical translation of this platform seems promising.

AB - Purpose: Urokinase-like Plasminogen Activator Receptor (uPAR) is overexpressed in a variety of carcinoma types, and therefore represents an attractive imaging target. The aim of this study was to assess the feasibility of two uPAR-targeted probes for PET and fluorescence tumor imaging in a human xenograft tongue cancer model. Experimental design and results: Tumor growth of tongue cancer was monitored by bioluminescence imaging (BLI) and MRI. Either ICG-Glu-Glu-AE105 (fluorescent agent) or 64Cu-DOTA-AE105 (PET agent) was injected systemically, and fluorescence imaging or PET/CT imaging was performed. Tissue was collected for micro-fluorescence imaging and histology. A clear fluorescent signal was detected in the primary tumor with a mean in vivo tumor-to-background ratio of 2.5. Real-time fluorescence-guided tumor resection was possible, and sub-millimeter tumor deposits could be localized. Histological analysis showed co-localization of the fluorescent signal, uPAR expression and tumor deposits. In addition, the feasibility of uPARguided robotic cancer surgery was demonstrated. Also, uPAR-PET imaging showed a clear and localized signal in the tongue tumors. Conclusions: This study demonstrated the feasibility of combining two uPARtargeted probes in a preclinical head and neck cancer model. The PET modality provided preoperative non-invasive tumor imaging and the optical modality allowed for real-time fluorescence-guided tumor detection and resection. Clinical translation of this platform seems promising.

KW - Head and neck cancer

KW - Image-guided surgery

KW - PET

KW - Robotic surgery

KW - Tumor margin assessment

KW - uPAR

U2 - 10.18632/oncotarget.14282

DO - 10.18632/oncotarget.14282

M3 - Journal article

C2 - 28039488

AN - SCOPUS:85014074259

VL - 8

SP - 15407

EP - 15419

JO - OncoTarget

JF - OncoTarget

SN - 1949-2553

IS - 9

ER -

ID: 188872606